このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Cumberland Pharmaceuticals マネジメント

マネジメント基準チェック /34

Cumberland Pharmaceuticals'の CEO はA. Kazimiで、 Jan1999年に任命され、の在任期間は 25.58年です。の年間総報酬は$ 1.17Mで、 57.7%給与と42.3%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の40.42%を直接所有しており、その価値は$ 7.63M 。経営陣と取締役会の平均在任期間はそれぞれ6.7年と11.3年です。

主要情報

A. Kazimi

最高経営責任者

US$1.2m

報酬総額

CEO給与比率	57.7%
CEO在任期間	25.7yrs
CEOの所有権	40.4%
経営陣の平均在職期間	6.8yrs
取締役会の平均在任期間	11.3yrs

経営陣の近況

Recent updates

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Mar 07

Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Prospects Need A Boost To Lift Shares

Jan 09

Why Investors Shouldn't Be Surprised By Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Low P/S

Oct 02

Health Check: How Prudently Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Use Debt?

Nov 09

We Think Some Shareholders May Hesitate To Increase Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) CEO Compensation

Apr 21

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Debt In A Risky Way?

Feb 13

One Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Analyst Just Cut Their EPS Forecasts

Nov 19

Cumberland Pharmaceuticals Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 11

CEO報酬分析

Cumberland Pharmaceuticals の収益と比較して、A. Kazimi の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-US$10m
Mar 31 2024	n/a	n/a	-US$8m
Dec 31 2023	US$1m	US$675k	-US$6m
Sep 30 2023	n/a	n/a	-US$2m
Jun 30 2023	n/a	n/a	-US$2m
Mar 31 2023	n/a	n/a	-US$4m
Dec 31 2022	US$1m	US$635k	-US$6m
Sep 30 2022	n/a	n/a	-US$7m
Jun 30 2022	n/a	n/a	-US$9m
Mar 31 2022	n/a	n/a	-US$7m
Dec 31 2021	US$1m	US$610k	-US$6m
Sep 30 2021	n/a	n/a	-US$3m
Jun 30 2021	n/a	n/a	-US$3m
Mar 31 2021	n/a	n/a	-US$5m
Dec 31 2020	US$1m	US$590k	-US$7m
Sep 30 2020	n/a	n/a	-US$8m
Jun 30 2020	n/a	n/a	-US$10m
Mar 31 2020	n/a	n/a	-US$10m
Dec 31 2019	US$1m	US$567k	-US$9m
Sep 30 2019	n/a	n/a	-US$8m
Jun 30 2019	n/a	n/a	-US$6m
Mar 31 2019	n/a	n/a	-US$6m
Dec 31 2018	US$1m	US$545k	-US$11m
Sep 30 2018	n/a	n/a	-US$6m
Jun 30 2018	n/a	n/a	-US$5m
Mar 31 2018	n/a	n/a	-US$9m
Dec 31 2017	US$1m	US$523k	-US$8m

報酬と市場: A.の総報酬 ($USD 1.17M ) は、 US市場 ($USD 681.57K ) の同規模の企業の平均を上回っています。

報酬と収益: A.の報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

A. Kazimi (66 yo)

25.7yrs

在職期間

US$1,169,530

報酬

Mr. A. J. Kazimi, MBA, founded Cumberland Pharmaceuticals Inc. in 1999 and has been its Chairman and Chief Executive Officer since 1999. Mr. Kazimi serves as the President of Cumberland Pharmaceuticals Inc...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
A. Kazimi	Founder	25.7yrs	US$1.17m	40.42% $ 7.0m
John Hamm	VP & CFO	3.3yrs	US$282.32k	0.18% $ 32.0k
James Herman	Executive VP of National Accounts & Chief Compliance Officer	7.9yrs	US$400.15k	0.27% $ 47.1k
Chris Bitterman	Vice President of Sales & Marketing	no data	US$316.29k	0.033% $ 5.8k
Todd Anthony	Vice President of Organizational Development	no data	US$330.85k	0.12% $ 20.1k
Jean Marstiller	Senior VP of Administrative Services & Corporate Secretary	no data	US$298.01k	データなし
Adam Mostafa	Managing Director	5.6yrs	データなし	データなし
Erin Gull	Senior Corporate Relations Associate	no data	データなし	データなし

6.8yrs

平均在職期間

66yo

平均年齢

経験豊富な経営陣: CPIXの経営陣は経験豊富で経験豊富です（平均在職期間は6.7年）。

取締役

名称	ポジション	在職期間	報酬	所有権
A. Kazimi	Founder	25.7yrs	US$1.17m	40.42% $ 7.0m
Joseph Williams	Member of Pharmaceutical Advisory Board	no data	データなし	データなし
Joseph Galante	Independent Director	6yrs	US$61.20k	0.42% $ 73.0k
Robert Roberts	Member of Medical Advisory Board	no data	データなし	データなし
Gordon Bernard	Chairman of Medical Advisory Board & Independent Director	14.7yrs	US$98.00k	データなし
J. Hix	Member of Pharmaceutical Advisory Board	no data	US$233.65k	データなし
Martin Brown	Director	2.2yrs	US$50.00k	0.043% $ 7.4k
David Warrell	Member of Medical Advisory Board	no data	データなし	データなし
Timothy Meakin	Member of Pharmaceutical Advisory Board	no data	データなし	データなし
Ben deBoisblanc	Member of Medical Advisory Board	no data	データなし	データなし
Caroline Young	Independent Director	8yrs	US$61.20k	0.20% $ 34.3k
James Jones	Independent Director	14.7yrs	US$60.20k	データなし

11.3yrs

平均在職期間

72yo

平均年齢

経験豊富なボード: CPIXの取締役会は経験豊富で経験豊富です ( 11.3年の平均在任期間)。

Cumberland Pharmaceuticals マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Cumberland Pharmaceuticals Inc., Annual General Meeting, Apr 23, 2024

Cumberland Pharmaceuticals Inc. Announces Demise of Joey A. Jacobs, Member of Board of Directors

Cumberland Pharmaceuticals Appoints Martin Brown Jr. to Its Board of Directors

Cumberland Pharmaceuticals Appoints Martin Brown Jr. to Its Board of Directors

Cumberland Pharmaceuticals Inc. Announces Executive Changes

Insufficient new directors

Recent updates

Second quarter 2024 earnings released: US$0.077 loss per share (vs US$0.061 profit in 2Q 2023)

Cumberland Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings released: US$0.14 loss per share (vs US$0.013 profit in 1Q 2023)

Cumberland Pharmaceuticals Inc. to Report Q1, 2024 Results on May 07, 2024

Cumberland Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $5.8 million.

New minor risk - Share price stability

Cumberland Pharmaceuticals Inc., Annual General Meeting, Apr 23, 2024

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Full year 2023 earnings released: US$0.44 loss per share (vs US$0.38 loss in FY 2022)

Cumberland Pharmaceuticals Inc. to Report Fiscal Year 2023 Results on Mar 05, 2024

Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Prospects Need A Boost To Lift Shares

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: US$0.073 loss per share (vs US$0.028 loss in 3Q 2022)

Cumberland Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 07, 2023

Cumberland Pharmaceuticals Inc. Announces New Antimicrobial Agents and Chemotherapy Detaining the Results of the First Clinical Study Investigating the Safety and Pharmacokinetics of Vibativ®? Injection in Children 2 to 17 Years of Age

New minor risk - Share price stability

Why Investors Shouldn't Be Surprised By Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Low P/S

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Second quarter 2023 earnings released: EPS: US$0.061 (vs US$0.091 loss in 2Q 2022)

Cumberland Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 08, 2023

Cumberland Pharmaceuticals Inc. Announces the Publication of Positive Results from Clinical Study Investigating the Safety and Pharmacokinetics of Caldolor in Newborn Infants, Published in the Journal Pediatric Drugs

Cumberland Pharmaceuticals Inc. Announces FDA Clearance of IND for New Treatment of Idiopathic Pulmonary Fibrosis

U.S. Food and Drug Administration Approves Cumberland Pharmaceuticals Inc.'s Expanded Lab Labulation for Caldolor

First quarter 2023 earnings released: EPS: US$0.013 (vs US$0.094 loss in 1Q 2022)

Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Have A Healthy Balance Sheet?

Full year 2022 earnings released: US$0.38 loss per share (vs US$0.37 loss in FY 2021)

Cumberland Pharmaceuticals Inc. Announces Demise of Joey A. Jacobs, Member of Board of Directors

Cumberland Pharmaceuticals Inc. Announces Approval of Supplemental New Drug Application from U.S. Food and Drug Administration

Third quarter 2022 earnings released: US$0.028 loss per share (vs US$0.10 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.028 loss per share (vs US$0.10 loss in 3Q 2021)

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Cumberland Pharmaceuticals Inc. to Report Q3, 2022 Results on Nov 08, 2022

Second quarter 2022 earnings released: US$0.091 loss per share (vs US$0.049 profit in 2Q 2021)

Cumberland Pharmaceuticals Inc. to Report Q2, 2022 Results on Aug 09, 2022

Cumberland Pharmaceuticals Appoints Martin Brown Jr. to Its Board of Directors

Calculating The Fair Value Of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)

Cumberland Pharmaceuticals Appoints Martin Brown Jr. to Its Board of Directors

Cumberland Pharmaceuticals Inc. Announces Executive Changes

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Cumberland Pharmaceuticals Inc. to Report Q1, 2022 Results on May 10, 2022

Insufficient new directors

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Tabuk and Cumberland Partner to Bring Innovative Antibiotic with Life-Saving Potential to Middle East

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Cumberland Pharmaceuticals Inc. to Report Fiscal Year 2021 Results on Mar 08, 2022

Now 22% undervalued

Cumberland Pharmaceuticals Inc. (NasdaqGS:CPIX) acquired SANCUSO from Kyowa Kirin, Inc. for $17 million.

Checking In On Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. Receives FDA Approval for Expanded Labeling for Caldolor®

Third quarter 2021 earnings released: US$0.10 loss per share (vs US$0.083 loss in 3Q 2020)

Health Check: How Prudently Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Use Debt?

Consensus forecasts updated

Second quarter 2021 earnings released: EPS US$0.049 (vs US$0.11 loss in 2Q 2020)

Cumberland Pharmaceuticals Inc.(NasdaqGS:CPIX) dropped from Russell Microcap Growth Index

Cumberland Pharmaceuticals Inc. Releases a Series of Case Reports Describing the Effectiveness of Vibativ® (Telavancin) in Treating Secondary Bacterial Infections in COVID-19 Patients

Consensus EPS estimates increase to -US$0.18

We Think Some Shareholders May Hesitate To Increase Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) CEO Compensation

Cumberland Pharmaceuticals Inc., Annual General Meeting, Apr 27, 2021

Full year 2020 earnings released: US$0.43 loss per share (vs US$0.23 loss in FY 2019)

Revenue beats expectations

Cumberland Pharmaceuticals Inc. to Report Q4, 2020 Results on Mar 09, 2021

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Debt In A Risky Way?

New 90-day high: US$3.31

New 90-day high: US$3.22

Analysts update estimates

One Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Analyst Just Cut Their EPS Forecasts

Cumberland Pharmaceuticals Inc. Announces the Launch of Reditrex® (Methotrexate) Injection

Revenue beats expectations, earnings disappoint

Third quarter 2020 earnings released: US$0.083 loss per share

マネジメント基準チェック /34